After the recent announcement of the first 10 drugs selected for Medicare price negotiation, much has been discussed about the drugs that were selected and the magnitude of price decreases that can be achieved. Less attention has been given to what this all means for Medicare beneficiaries.The negotiation, informed by confidential data from manufacturers and […]

Author